Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 78 peer-reviewed journal articles Updated
Cardiology · LMNA-Related Familial Dilated Cardiomyopathy With Conduction Defect

Familial dilated cardiomyopathy with conduction defect due to LMNA mutation: A Patient Guide

At a Glance

LMNA-related familial dilated cardiomyopathy can disrupt the heart’s electrical system before the heart muscle weakens. Because rhythm risk varies and may exist with normal pumping strength, ongoing monitoring, genetic family screening, and individualized device discussions are important.

Familial dilated cardiomyopathy with conduction defect due to LMNA mutation is a genetic heart condition that affects both the physical structure and the electrical timing of the heart [1]. It is caused by a change in the LMNA gene, which normally provides the instructions for building proteins that act as a “scaffold” for the control center of your heart cells. When this scaffold is weak, the constant mechanical stress of the heart’s beating can lead to cellular damage over time [2][3]. This process often results in the heart chambers becoming enlarged with impaired contraction—a state called dilated cardiomyopathy—which can eventually reduce the heart’s ability to pump blood effectively [4].

What this diagnosis does and does not mean: A pathogenic variant in the LMNA gene raises your risk for heart complications, but it does not predict the exact age they will start, the severity of the disease, or whether you will definitely need a device. The course is highly individualized.

A unique and critical feature of this condition is that the heart’s “electrical wiring” is often affected long before the heart muscle itself begins to weaken [5]. Many people first notice symptoms like a slow heartbeat (conduction block) or irregular rhythms such as atrial fibrillation [6]. Because the electrical system can be unstable even when the heart’s pumping power, or ejection fraction, appears normal, doctors do not rely on pumping strength alone to determine your safety [7][8]. Instead, they use specialized risk models to watch for “short circuits” that could lead to sudden cardiac events, often recommending shared decision-making around protective devices like an ICD (implantable cardioverter-defibrillator) [9]. A normal LVEF does not eliminate arrhythmic risk, but it also does not mandate an immediate device.

Because this condition is inherited, a diagnosis for one person is often a starting point for the entire family [10]. Each child of a person with an LMNA mutation has a 50% chance of inheriting the gene, though the age at which symptoms appear can vary significantly from one relative to the next [11][4]. Cascade screening, which involves testing and monitoring close relatives even if they feel perfectly healthy, is a vital step in preventing emergencies and ensuring that everyone in the family receives the protective care they need [1].

Living with LMNA-related disease requires a lifelong partnership with a specialized care team, typically including cardiologists who focus on heart rhythms, heart failure, and genetics [12]. While the diagnosis is serious and the condition can progress, modern medicine offers a clear roadmap for management through advanced medications, rhythm-monitoring technology, and proactive risk assessment [8][4]. By staying closely connected to an experienced clinical team, you can navigate these challenges with the most current evidence and support, focusing on protecting your heart and your family’s future [13].

In this guide

6 chapters

01

Understanding LMNA-Related Cardiomyopathy

Learn how LMNA-related cardiomyopathy affects heart rhythm and pumping, why family screening matters, and how ECGs, imaging, and ICD decisions guide care.

02

Symptoms and Urgent Warning Signs of LMNA-CM

Learn to recognize LMNA-CM symptoms, fainting, palpitations with dizziness, slow heart rates, and when to call emergency services or your cardiology team.

03

Diagnosis and Genetic Subtypes of LMNA-CM

Learn how LMNA-CM is diagnosed through EKG, imaging, and genetic testing, and what genetic subtypes, overlapping symptoms, and family screening mean for you.

04

Advanced Risk Stratification and Monitoring

Learn how LMNA-related dilated cardiomyopathy risk is monitored, including LGE on cardiac MRI, NSVT, ejection fraction, and when an ICD may be discussed.

05

Devices and Heart Rhythm Management

Learn how LMNA-related cardiomyopathy is managed with ICDs, pacemakers, CRT, AFib blood thinners, and VT ablation, including device safety and follow-up.

06

Heart Failure Treatment and Advanced Care

Learn how LMNA cardiomyopathy is treated, including heart failure medicines, rhythm care, daily monitoring, LVADs, transplant, and when to seek advanced care.

Common questions in this guide

What does a pathogenic LMNA variant mean for my heart?
A pathogenic LMNA variant can make the heart’s supporting structure less stable, leading to an enlarged, weaker heart and problems with the heart’s electrical system. It increases risk but does not tell exactly when problems will begin, how severe they will be, or whether you will need a device.
Can I have dangerous rhythm problems if my ejection fraction is normal?
Yes. In LMNA-related cardiomyopathy, conduction problems and abnormal rhythms can appear before the heart’s pumping strength falls, so a normal ejection fraction does not eliminate rhythm risk. Regular ECGs and rhythm monitoring help your care team assess your risk.
Will I automatically need an ICD if I have LMNA cardiomyopathy?
No. An ICD decision is individualized using your rhythm findings, clinical history, heart function, and specialized risk assessment, and should be discussed with your cardiology or electrophysiology team. A normal ejection fraction does not automatically rule out or require an ICD.
Should my children and siblings be tested for an LMNA mutation?
Because LMNA-related cardiomyopathy can be inherited, close relatives should discuss genetic counseling and cascade screening with a qualified team, even if they feel well. Each child of a person with an LMNA mutation has a 50% chance of inheriting the gene, and screening can help identify risk early.
What symptoms should I report to my cardiologist?
Tell your care team about a slow or irregular heartbeat, fluttering, racing or skipping sensations, near-fainting, or fainting. These symptoms can reflect conduction disease or an abnormal rhythm and should be clinically evaluated.
Which specialists should be part of my LMNA cardiomyopathy care team?
Care commonly involves a cardiologist with expertise in electrophysiology, a heart failure specialist, and a genetics professional or genetic counselor. The exact team depends on your heart findings, family history, and testing results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I have a specific 'pathogenic' mutation in the LMNA gene, and what does that mean for my family?
  2. 2.Are my current EKG and heart rhythm monitors showing any signs of conduction disease or arrhythmias?
  3. 3.Based on my current health, what is my individualized risk for a sudden heart event?
  4. 4.Who are the specialists (electrophysiologists, heart failure experts, geneticists) I should have on my care team?
  5. 5.How do we set up screening and genetic testing for my children and siblings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.

    Hasselberg NE, Haland TF, Saberniak J, et al.

    European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.

    PMID: 29095976
  2. 2

    Altering lamina assembly reveals lamina-dependent and -independent functions for A-type lamins.

    Zwerger M, Roschitzki-Voser H, Zbinden R, et al.

    Journal of cell science 2015; (128(19)):3607-20 doi:10.1242/jcs.171843.

    PMID: 26275827
  3. 3

    Nuclear shape is affected differentially by loss of lamin A, lamin C, or both lamin A and C.

    Pho M, Berrada Y, Gunda A, Stephens AD

    microPublication biology 2024; (2024()) doi:10.17912/micropub.biology.001103.

    PMID: 38440331
  4. 4

    LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.

    Rosario KF, Karra R, Amos K, et al.

    Journal of cardiac failure 2023; (29(12)):1657-1666 doi:10.1016/j.cardfail.2023.08.016.

    PMID: 37659618
  5. 5

    Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers.

    Kumar S, Baldinger SH, Gandjbakhch E, et al.

    Journal of the American College of Cardiology 2016; (68(21)):2299-2307 doi:10.1016/j.jacc.2016.08.058.

    PMID: 27884249
  6. 6

    Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy.

    Tremblay-Gravel M, Ichimura K, Picard K, et al.

    Circulation. Genomic and precision medicine 2023; (16(1)):e003480 doi:10.1161/CIRCGEN.121.003480.

    PMID: 36548481
  7. 7

    Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.

    Peretto G, Barison A, Forleo C, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1864-1872 doi:10.1093/europace/euaa171.

    PMID: 32995851
  8. 8

    Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry.

    Barriales-Villa R, Ochoa JP, Larrañaga-Moreira JM, et al.

    Revista espanola de cardiologia (English ed.) 2021; (74(3)):216-224 doi:10.1016/j.rec.2020.03.026.

    PMID: 32616434
  9. 9

    Missense and Non-Missense Lamin A/C Gene Mutations Are Similarly Associated with Major Arrhythmic Cardiac Events: A 20-Year Single-Centre Experience.

    Forleo C, Carella MC, Basile P, et al.

    Biomedicines 2024; (12(6)) doi:10.3390/biomedicines12061293.

    PMID: 38927500
  10. 10

    Clinical Features of LMNA-Related Cardiomyopathy in 18 Patients and Characterization of Two Novel Variants.

    Ferradini V, Cosma J, Romeo F, et al.

    Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215075.

    PMID: 34768595
  11. 11

    Lamin A/C Cardiomyopathy: Implications for Treatment.

    Chen SN, Sbaizero O, Taylor MRG, Mestroni L

    Current cardiology reports 2019; (21(12)):160 doi:10.1007/s11886-019-1224-7.

    PMID: 31773301
  12. 12

    Dilated Cardiomyopathy: A Genetic Journey from Past to Future.

    Newman NA, Burke MA

    International journal of molecular sciences 2024; (25(21)) doi:10.3390/ijms252111460.

    PMID: 39519012
  13. 13

    Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors.

    Miller EM, Brown E, Christian S, et al.

    Journal of genetic counseling 2025; (34(3)):e1993 doi:10.1002/jgc4.1993.

    PMID: 39484862

This page is for informational purposes only and does not constitute medical advice. Your cardiologist, electrophysiologist, and genetics team should interpret your LMNA results and discuss monitoring or ICD decisions for your situation.

Get notified when new evidence is published on Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.